Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

3038results about How to "Symptoms improved" patented technology

Humanization of antibodies

InactiveUS20050042664A1Limited diversityFast and less labor intensive productionHybrid immunoglobulinsMicrobiological testing/measurementAntigen bindingHumanized antibody
The present invention provides methods of re-engineering or re-shaping an antibody from a first species, wherein the re-engineered or re-shaped antibody does not elicit undesired immune response in a second species, and the re-engineered or re-shaped antibody retains substantially the same antigen binding-ability of the antibody from the first species. In accordance with the present invention, a combinatorial library comprising the CDRs of the antibody from the first species fused in frame with framework regions derived from a second species can be constructed and screened for the desired modified antibody. In particular, the present invention provides methods utilizing low homology acceptor antibody frameworks for efficiently humanizing an antibody or a fragment thereof. The present invention also provides antibodies produced by the methods of the invention.
Owner:MEDIMMUNE LLC

Anti-RSV antibodies

The present invention encompasses novel antibodies and fragments thereof which immunospecifically bind to one or more RSV antigens and compositions comprising said antibodies and antibody fragments. The present invention encompasses methods preventing respiratory syncytial virus (RSV) infection in a human, comprising administering to said human a prophylactically effective amount of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein a certain serum titer of said antibodies or antibody fragments is achieved in said human subject. The present invention also encompasses methods for treating or ameliorating symptoms associated with a RSV infection in a human, comprising administering to said human a therapeutically effective amount of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein a certain serum titer of said antibodies or antibody fragments is achieved in said human subject. The present invention further encompasses compositions comprising antibodies or fragments thereof that immunospecifically bind to a RSV antigen, and methods using said compositions for detection or diagnosis a RSV infection.
Owner:MEDIMMUNE LLC

Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth

InactiveUS6861053B1Eradicate small intestinal bacterial overgrowthSymptoms improvedAntibacterial agentsOrganic active ingredientsBacteroidesAutoimmune responses
Disclosed is a method of diagnosing irritable bowel syndrome, fibromyalgia, chronic fatigue syndrome, depression, attention deficit / hyperactivity disorder, autoimmune diseases, such as multiple sclerosis and systemic lupus erythematosus, or Crohn's disease, which involves detecting the presence of small intestinal bacterial overgrowth (SIBO) in a human subject having at least one symptom associated with a suspected diagnosis of any of those diagnostic categories. Also disclosed is a method of treating these disorders, and other disorders caused by SIBO, that involves at least partially eradicating a SIBO condition in the human subject. The method includes administration of anti-microbial or probiotic agents, or normalizing intestinal motility by employing a prokinetic agent. The method improves symptoms, including hyperalgesia related to SIBO and disorders caused by SIBO. Also disclosed is a kit for the diagnosis or treatment of irritable bowel syndrome, fibromyalgia, chronic fatigue syndrome, depression, attention deficit / hyperactivity disorder, autoimmune diseases, or Crohn's disease.
Owner:CEDARS SINAI MEDICAL CENT

Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment

The present invention encompasses novel antibodies and fragments thereof which immunospecifically bind to one or more RSV antigens and compositions comprising said antibodies and antibody fragments. The present invention encompasses methods preventing respiratory syncytial virus (RSV) infection in a human, comprising administering to said human a prophylactically effective amount of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein a certain serum titer of said antibodies or antibody fragments is achieved in said human subject. The present invention also encompasses methods for treating or ameliorating symptoms associated with a RSV infection in a human, comprising administering to said human a therapeutically effective amount of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein a certain serum titer of said antibodies or antibody fragments is achieved in said human subject. The present invention further encompasses compositions comprising antibodies or fragments thereof that immunospecifically bind to a RSV antigen, and methods using said compositions for detection or diagnosis a RSV infection.
Owner:MEDIMMUNE LLC

B-cell reduction using CD37-specific and CD20-specific binding molecules

The present invention generally provides methods for B-cell reduction in an individual using CD37-specific binding molecules. In particular, the invention provides methods for B-cell reduction using CD37-specific binding molecules alone, or a combination of CD37-specific binding molecules and CD20-specific binding molecules, in some instances a synergistic combination. The invention further provides materials and methods for treatment of diseases involving aberrant B-cell activity. In addition, the invention provides humanized CD37-specific binding molecules.
Owner:APTEVO RES & DEV LLC

Methods and compositions for treating pulmonary hypertension

InactiveUS20100166869A1Pulmonary hypertension is delayedReduce pressureBiocidePowder deliveryNanoparticleCarrier protein
The present invention features methods for treating, stabilizing, preventing, and / or delaying pulmonary hypertension by administering nanoparticles that comprise rapamycin or a derivative thereof and / or nanoparticles that comprise a taxane (e.g., paclitaxel) or a derivative thereof. The invention also provides compositions (e.g., unit dosage forms) comprising nanoparticles that comprise a carrier protein and rapamycin or a derivative thereof and / or nanoparticles that comprise a carrier protein and a taxane (e.g. paclitaxel) or a derivative thereof.
Owner:ABRAXIS BIOSCI LLC

Recombinant IL-9 antibodies and uses thereof

InactiveUS20050002934A1Reduces function and activity and expressionReduced activityAntibacterial agentsNervous disorderAutoimmune diseaseImmunologic specificity
The present invention provides novel antibodies that immunospecifically bind to an IL-9 polypeptide and compositions comprising said antibodies. The present invention also provides methods and compositions preventing, treating, managing, and / or ameliorating diseases and disorders associated with aberrant expression and / or activity of IL 9 or IL-9 receptor or subunits thereof, autoimmune diseases, inflammatory diseases, proliferative diseases, and infections comprising administration of one or more antibodies thereof that immunospecifically bind to an IL-9 polypeptide. The invention also encompasses methods and compositions for diagnosing, monitoring, and prognosing these disorders. The present invention further relates to articles of manufacture and kits comprising antibodies that immunospecifically bind to an IL-9 polypeptide.
Owner:MEDIMMUNE LLC

Compounds and methods for the targeted degradation of bromodomain-containing proteins

The present invention relates to bifunctional compounds, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins which are degraded and / or otherwise inhibited by bifunctional compounds according to the present invention. In particular, the present invention is directed to compounds, which contain on one end a VHL ligand which binds to the ubiquitin ligase and on the other end a moiety which binds a target protein such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of that protein. The present invention exhibits a broad range of pharmacological activities associated with compounds according to the present invention, consistent with the degradation / inhibition of targeted polypeptides.
Owner:ARVINAS OPERATIONS INC +1

Method of treating and diagnosing parkinsons disease and related dysautonomic disorders

InactiveUS20070053895A1Symptoms improvedNervous disorderPeptide/protein ingredientsAutonomic bladder dysfunctionPsychiatry
A method for treating a Parkinson's patient with digestive / pancreatic enzymes involves administering an effective amount of digestive / pancreatic enzymes to an individual having the disorder in order to improve a symptom of the disorder. In addition, a method is provided for determining whether an individual has, or may develop, Parkinson's disease or related dysautonomic disorders and for determining whether an individual will benefit from the administration of pancreatic / digestive enzymes to treat the dysautonomic disorder.
Owner:CUREMARK

B-cell reduction using cd37-specific and cd20-specific binding molecules

The present invention generally provides methods for B-cell reduction in an individual using CD37-specific binding molecules. In particular, the invention provides methods for B-cell reduction using CD37-specific binding molecules alone, or a combination of CD37-specific binding molecules and CD20-specific binding molecules, in some instances a synergistic combination. The invention further provides materials and methods for treatment of diseases involving aberrant B-cell activity. In addition, the invention provides humanized CD37-specific binding molecules.
Owner:EMERGENT PRODUCTS DEVELOPMENT SEATTLE LLC

Implantation rates after in vitro fertilization, treatment of infertility and early pregnancy loss with a nitric oxide donor alone or in combination with progesterone, and a method for contraception with nitric oxide inhibitors

A method is provided for the improvement of implantation rates and / or pregnancy rates in a female mammal, comprising administering to a female mammal in whom pregnancy is desired an effective amount of (a) a nitric oxide synthase substrate, a nitric oxide donor, or both, optionally in combination with (b) a progestin, and, (c) optionally, in further combination with an estrogen. A method is also provided for fertility control for a female mammal, comprising administering to a female mammal in whom pregnancy is not desired and at risk for becoming pregnant an effective amount of nitric oxide synthase inhibitor in combination with an antiprogestin. Pharmaceutical compositions are also provided.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST

Regulation of oncogenes by microRNAs

Naturally occurring miRNAs that regulate human oncogenes and methods of use therof are described. Suitable nucleic acids for use in the methods and compositions described herein include, but are not limited to, pri-miRNA, pre-miRNA, mature miRNA or fragments of variants thereof that retain the biological activity of the mature miRNA and DNA encoding a pri-miRNA, pre-miRNA, mature miRNA, fragments or variants thereof, or regulatory elements of the miRNA. The compositions containing nucleic acids are administered to a patient in need of treatment or prophylaxis of at least one symptom or manifestation of cancer. In one embodiment, the compositions are administered in an effective amount to inhibit gene expression of one or more oncogenes. Methods for treatment or prevention of at least one symptom or manifestation of cancer are also described.
Owner:YALE UNIV

Method and system for modulating energy expenditure and neurotrophic factors

A method system for modulating the energy expenditure and / or the expressed brain-derived neurotrophic factor (BDNF) in the brain of an individual is performed by a system that includes a control device that generates a stimulation pattern from a predetermined set of stimulation parameters, and that converts the stimulation pattern into a stimulation signal. A stimulation signal delivery mechanism, configured for implantation into a selected part of the brain, receives the stimulation signal from the control device and delivers the signal to the selected part of the brain. The stimulation signal may be an electrical signal delivered by a brain-implantable electrode, or a chemical signal in the form of a drug dosage regimen delivered by an implantable micropump under the control of the control device. Modulation of the energy expenditure and / or BDNF is achieved by the stimulation of the hypothalamus, either directly or indirectly, by the stimulation signal.
Owner:RGT UNIV OF CALIFORNIA

Machine learning based system for identifying and monitoring neurological disorders

A system and methods of diagnosing and monitoring neurological disorders in a patient utilizing an artificial intelligence based system. The system may comprise a plurality of sensors, a collection of trained machine learning based diagnostic and monitoring tools, and an output device. The plurality of sensors may collect data relevant to neurological disorders. The trained diagnostic tool will learn to use the sensor data to assign risk assessments for various neurological disorders. The trained monitoring tool will track the development of a disorder over time and may be used to recommend or modify the administration of relevant treatments. The goal of the system is to render an accurate evaluation of the presence and severity of neurological disorders in a patient without requiring input from an expertly trained neurologist.
Owner:RAO SATISH +1

Health-care flour composition and food

The invention provides a health-care flour composition and food and a preparing method thereof. According to the preparing method, hericium erinaceus and flour are used as main raw materials, swelling agents, sweetening agents, oil, salt and the like are added and mixed with water, and then rolling, forming, baking, oil injection and cooling are carried out to obtain various foods made of flour or pastries such as cookies, cakes and noodles. The health-care flour composition and food are even in texture, capable of being stored for a long time easily, good in mouthfeel and rich in nutrient, and market vacancy is filled. The health-care flour composition and food have definite effects in repairing gastric mucosal damage caused by chronic gastritis, or gastric ulcers or duodenal ulcers, relieving abdominal pains caused by chronic gastritis, or gastric ulcers or duodenal ulcers, inhibiting helicobacter pylori, and assisting the treatment of chronic gastritis, gastric ulcers and duodenal ulcers.
Owner:江中食疗科技有限公司

Ventilatory assistance for treatment of cardiac failure and Cheyne-Stokes breathing

Method and apparatus for the treatment of cardiac failure, Cheyne Stokes breathing or central sleep apnea are disclosed. A subject is provided with ventilatory support, for example positive pressure ventilatory support using a blower and mask. Respiratory airflow is determined. From the respiratory airflow are derived a measure of instantaneous ventilation (for example half the absolute value of the respiratory airflow) and a measure of longterm average ventilation (for example the instantaneous ventilation low pass filtered with a 100 second time constant). A target ventilation is taken as 95% of the longterm average ventilation. The instantaneous ventilation is fed as the input signal to a clipped integral controller, with the target ventilation as the reference signal. The output of the controller determines the degree of ventilatory support. Clipping is typically to between half and double the degree of support that would do all the respiratory work. A third measure of ventilation, for example instantaneous ventilation low pass filtered with a time constant of 5 seconds, is calculated. Ventilatory support is in phase with the subject's respiratory airflow to the fuzzy extent that this ventilation is above target, and at a preset rate conversely.
Owner:RESMED LTD

Biofilm formation to define risk for colon cancer

Methods of identifying subjects at increased risk of cancer, based upon detection of biofilms and / or biofilm-associated microbes within a subject, are disclosed. Therapies designed to prevent formation and / or reduce the size of biofilms in a subject identified to be at increased risk of cancer based upon detection of biofilms and / or biofilm-associated microbes are disclosed. In particular embodiments, the invention provides for identification of a subject at elevated risk of developing or having colorectal cancer and / or a colorectal adenoma, based upon detection of a biofilm and / or biofilm-associated bacteria within the gastrointestinal tract of the subject (optionally, within a biopsy specimen and / or stool sample of such subject). Therapies involving administration of an antibiotic agent and / or a probiotic agent to a subject, to prevent or reduce biofilm formation within the gastrointestinal tract of the subject, optionally provided in combination with additional cancer therapy, are also disclosed.
Owner:THE JOHN HOPKINS UNIV SCHOOL OF MEDICINE

Methods and compositions for sleep disorders and other disorders

Use of particular substituted heterocycle fused gamma-carboline compounds as pharmaceuticals and pharmaceutical compositions comprising them for the treatment of one or more disorders involving the 5-HT2A, SERT and / or dopamine D2 pathways are disclosed. In addition, the compounds may be combined with other therapeutic agents for the treatment of one or more sleep disorders, depression, psychosis, dyskinesias, and / or Parkinson's disease or any combinations.
Owner:INTRA CELLULAR THERAPIES INC

Bile Acid Recycling Inhibitors for Treatment of Hypercholemia and Cholestatic Liver Disease

Provided herein are methods of treating or ameliorating hypercholemia or a cholestatic liver disease by administering to an individual in need thereof a therapeutically effective amount of an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTI) or a pharmaceutically acceptable salt thereof. Also provided are methods for treating or ameliorating a liver disease, decreasing the levels of serum bile acids or hepatic bile acids, treating or ameliorating pruritis, reducing liver enzymes, or reducing bilirubin comprising administering to an individual in need thereof a therapeutically effective amount of ASBTI or a pharmaceutically acceptable salt thereof.
Owner:LUMENA PHARMA INC

Use of somatostatin receptor agonists in the treatment of human disorders of sleep hypoxia and oxygen deprivation

InactiveUS20030083241A1Inhibition of activationBroad anti-inflammatory activityAntinoxious agentsSomatostatinsOxygen deprivationHypopnea
The invention relates to a method of treating diverse human disorders that may arise, in part, out of sleep hypoxia and oxygen deprivation occurring in the context of sleep apnea / hypopnea disturbances. The disorders that may be treated by the invention comprise gastroesophageal reflux disease (GERD), asthma-associated gastroesophageal reflux (GER), GER-associated asthma, asthma, cardiomyopathy, cardioarrhythmia, congestive heart failure, sudden infant death syndrome, and diverse neurologic conditions. The mode of treatment uses somatostatin receptor ligands (SstRLs), particularly somatostatin-receptor agonists. The invention concerns the method of treatment utilizing, and compositions comprising SstRLs and somatostatin receptor agonists, including agonists of the somatostatin receptor types 2 and 5, particularly, the type 2A receptor (SsR-2A), including octreotide and lanreotide.
Owner:YOUNG CHARLES W

Nucleic acid molecules encoding a 103 gene product and uses therefor

InactiveUS6323334B1Decrease in production levelReduce in quantityBacteriaPeptide/protein ingredientsAntigenNucleotide
The present invention relates to methods and compositions for the treatment and diagnosis of immune disorders, especially T helper lymphocyte-related disorders. In particular, the invention provides a nucleotide sequence which encodes a previously unknown human 103 gene product. The invention also provides expression vectors containing the nucleic acid molecules of the invention and host cells into which the expression vectors have been introduced. The invention still further provides isolated polypeptides, fusion polypeptides, antigenic peptides and antibodies.
Owner:MILLENNIUM PHARMA INC

Methods of administering/dosing CD2 antagonists for the prevention and treatment of autoimmune disorders or inflammatory disorders

The present invention provides compositions for the prevention or treatment of an autoimmune disorder or an inflammatory disorder in a subject comprising one or more CD2 antagonists. In particular, the invention provides methods for preventing or treating an autoimmune disorder or an inflammatory disorder in a subject comprising administering one or more CD2 binding molecules to said subject. The present invention provides doses of CD2 binding molecules and methods of administration that result in improved efficacy, while avoiding or reducing the adverse or unwanted side effects associated with the administration of an agent that induces the depletion of peripheral blood lymphocytes.
Owner:MEDIMMUNE LLC

Methods for treating pervasive development disorders

A method of utilizing the chymotrypsin level of an individual as a measure of the success of secretin, other neuropeptides, and peptides or digestive enzyme administration to such individuals, and in particular, as a prognosticative of potential secretin, other neuropeptides, peptides, and digestive enzyme administration for persons having ADHD, Autism and other PDD related disorders. In one aspect, a method for determining the efficacy of secretin, other neuropeptides, peptides, or digestive enzymes for the treatment of an individual diagnosed with a pervasive developmental disorder (PDD) comprises obtaining a sample of feces from an individual, determining a quantitative level of chymotrypsin present in the sample, and correlating the quantitative level of chymotrypsin determined to be present in the sample with the PDD to determine the efficacy of treating the individual with secretin, other neuropeptides, peptides, or digestive enzyme administration. In another aspect, a therapeutic method for treating an individual diagnosed with i PDD pervasive developmental disorder comprises determining the efficacy of secretin, other neuropeptides, peptides, and digestive enzyme administration for the treatment of the individual based on a measure of the individual's chymotrypsin level, and administering secretin, other neuropeptides, peptides, or digestive enzymes to the individual based on the determination of the measure of the individual's chymotrypsin level.
Owner:CUREMARK

Mobile Healthcare Development, Communication, And Management

InactiveUS20140278536A1Facilitate communicationFacilitates and strengthens a healthcare provider's careData processing applicationsTelemedicineApplication softwareComputer science
A computer implemented method and system provides a mobile application development platform (MADP) for dynamically creating a healthcare provider specific customizable composite mobile application (CCMA) and monitoring healthcare elements of a healthcare recipient using the CCMA. The MADP is accessible by a healthcare provider device and a healthcare recipient device via a network. The MADP stores multiple template objects, for example, sub-applications that perform tasks for monitoring the healthcare elements in an application management database (AMD). The MADP acquires a selection of one or more template objects and one or more dynamic content objects defined by a healthcare provider and dynamically creates the CCMA by integrating the selected template objects and dynamic content objects. The MADP stores the CCMA in the AMD. The CCMA facilitates communication between the healthcare provider device and the healthcare recipient device for monitoring the healthcare elements of the healthcare recipient.
Owner:BLUEJAY MOBILE HEALTH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products